Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.50 |
| ▸ | LPL | P06858 | 6/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.50 |
| ▸ | F11 | P03951 | 3/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13507405 | 0.86 | LPL (0.50) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL25688 | 0.85 | LPL (0.49) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL18615134 | 0.82 | LPL (0.53) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL21370131 | 0.82 | LPL (0.53) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL4290411 | 0.82 | LPL (0.53) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL418767 | 0.82 | LPL (0.56) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL15615747 | 0.81 | LPL (0.49) | LPLLIPGF11F2PRSS1 | |
| SCHEMBL2030174 | 0.81 | LIPG (0.43) | NR1H2NR1H3LPLLIPGF11 | |
| SCHEMBL25985482 | 0.81 | LIPG (0.54) | NR1H2NR1H3LPLLIPGF11 | |
| SCHEMBL18595639 | 0.81 | LPL (0.45) | LPLLIPGF11F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-113666853-B | Biaryl compounds useful as ROR gamma modulators | 上海辉启生物医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2022095971-A1 | SPIRO HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海医药集团股份有限公司 | 2022-05-12 | — | — | WO | disclosed |
| CN-114437096-A | Spiro-heterocyclic compound, and preparation method and application thereof | 上海医药集团股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-20220106323-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2022-04-07 | — | — | US | disclosed |
| US-20220106323-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2022-04-07 | — | — | US | disclosed |
| US-20220106329-A1 | BICYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B V (US) | 2022-04-07 | — | — | US | disclosed |
| US-11242350-B2 | Spirocyclic ROR-gamma modulators | ESCALIER BIOSCIENCES B.V. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242350-B2 | Spirocyclic ROR-gamma modulators | ESCALIER BIOSCIENCES B.V. (US) | 2022-02-08 | — | — | US | disclosed |
| US-7956052-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-07 | — | — | US | disclosed |
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010023317-A1 | NOVEL HEXAFLUORO-2-BIPHENYLISOPROPANOL COMPOUNDS THAT MODULATE LXR-TYPE RECEPTORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS IN HUMAN AND VETERINARY MEDICINE AND ALSO IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-03-04 | — | — | WO | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | NR1H2 149/4885NR1H3 191/4885LPL 580/4885 |
| US-11242350-B2 | Spirocyclic ROR-gamma modulators | RORA, RORC, RORB | NR1H2 11/4885NR1H3 13/4885LPL 1723/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | NR1H2 493/4885NR1H3 955/4885LPL 2155/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | NR1H2 1061/4885NR1H3 1039/4885LPL 3618/4885 |
| US-20220106323-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | RORA, RORC, RORB | NR1H2 11/4885NR1H3 13/4885LPL 1723/4885 |
| US-20220106329-A1 | BICYCLIC ROR-GAMMA MODULATORS | RORA, RORC, RORB | NR1H2 11/4885NR1H3 14/4885LPL 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.